INDOLE DERIVATIVES

Abstract: The invention relates to compounds of formula (I): wherein Im represents an imidazolyl group of formula : R¹ represents a hydrogen atom or a group selected from C 1-6 alkyl, C 3-6 alkenyl, C 3-10 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-4 alkyl, phenyl, phenylC 1-3 alkyl, -CO₂R⁸, -COR⁸, -CONR⁸R⁹ or -SO₂R⁸ (wherein R⁸ and R⁹, which may be the same or different, each represents a hydrogen atom, a C 1-6 alkyl or C 3-7 cycloalkyl group, or a phenyl or phenylC 1-4 alkyl group, in which the phenyl group is optionally substituted by one or more C 1-4 alkyl, C 1-4 alkoxy or hydroxy groups or halogen atoms, with the proviso that R⁸ does not represent a hydrogen atom when R¹ represents a group -CO₂R⁸ or -SO₂R⁸); R₂ represents a hydrogen atom or a C 1-6 alkyl, C 3-6 alkenyl, C 3-7 cycloalkyl, phenyl or phenylC 1-3 alkyl group; R³ and R⁴, which may be the same or different, each represents a hydrogen atom or a C 1-6 alkyl group; one of the groups represented by R⁵, R⁶ and R⁷ is a hydrogen atom or a C 1-6 alkyl, C 3-7 cycloalkyl, C 3-6 alkenyl, phenyl or phenylC 1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C 1-6 alkyl group; Q represents a hydrogen atom or a halogen atom or a hydroxy, C 1-4 alkoxy, phenylC 1-3 alkoxy or C 1-6 alkyl group or a group -NR¹⁰R¹¹ or -CONR¹⁰R¹¹ (wherein R¹⁰ and R¹¹, which may be the same or different, each represents a hydrogen atom or a C 1-4 alkyl or C 3-4 alkenyl group, or together with the nitrogen atom to which they are attached form a saturated 5 to 7 membered ring); and with the proviso that when Q represents a hydrogen atom R¹ represents -CO₂R⁸, -COR⁸, -CONR⁸R⁹ or -SO₂R⁸; and physiologically acceptable salts and solvates thereof. The compounds are potent and selective antagonists of the effect of 5-HT at 5-HT₃ receptors and are useful, for example, in the treatment of psychotic disorders, anxiety, and nausea and vomiting.

Description: This invention relates to indole derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their medical use. In particular the invention relates to compounds which act upon 5-hydroxytryptamine (5-HT) receptors of the type located on terminals of primary afferent nerves. Compounds having antagonist activity at 'neuronal' 5-HT receptors of the type located on primary afferent nerves have been described previously. Thus for example published UK Patent Specification No. 2153821A and published European Patent Specification No. 191562 disclose tetrahydrocarbazolones of the general formula wherein R¹ represents a hydrogen atom or a C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-4 alkyl, C 3-6 alkenyl, C 3-10 alkynyl, phenyl or phenylC 1-3 alkyl group, and one of the groups represented by R², R³ and R⁴ is a hydrogen atom or a C 1-6 alkyl, C 3-7 cycloalkyl, C 2-6 alkenyl or phenylC 1-3 alkyl group and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C 1-6 alkyl group. We have now found a novel group of compounds which differ in structure from those described previously, and which are potent antagonists of the effect of 5-HT at 5-HT 'neuronal' receptors. Thus, in one aspect the present invention provides an indole of the general formula (I): wherein Im represents an imidazolyl group of formula: R¹ represents a hydrogen atom or a group selected from C 1-6 alkyl, C 3-6 alkenyl, C 3-10 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-4 alkyl, phenyl, phenylC 1-3 alkyl, -CO₂R⁸, -COR⁸, -CONR⁸R⁹ or -SO₂R⁸ (wherein R⁸ and R⁹, which may be the same of different, each represents a hydrogen atom, a C 1-6 alkyl or C 3-7 cycloalkyl group, or a phenyl or phenylC 1-4 alkyl group, in which the phenyl group is optionally substituted by one or more C 1-4 alkyl, C 1-4 alkoxy or hydroxy groups or halogen atoms, with the proviso that R⁸ does not represent a hydrogen atom when R¹ represents a group -CO₂R⁸ or -SO₂R⁸); R₂ represents a hydrogen atom or a C 1-6 alkyl, C 3-6 alkenyl, C 3-7 cycloalkyl, phenyl or phenylC 1-3 alkyl group; R³ and R⁴, which may be the same or different, each represents a hydrogen atom or a C 1-6 alkyl group; one of the groups represented by R⁵, R⁶ and R⁷ is a hydrogen atom or a C 1-6 alkyl, C 3-7 cycloalkyl, C 3-6 alkenyl, phenyl or phenylC 1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C 1-6 alkyl group; Q represents a hydrogen atom or a halogen atom or a hydroxy, C 1-4 alkoxy, phenylC 1-3 alkoxy or C 1-6 alkyl group or a group -NR¹⁰R¹¹ or -CONR¹⁰R¹¹ (wherein R¹⁰ and R¹¹, which may be the same or different, each represents a hydrogen atom or a C 1-4 alkyl or C 3-4 alkenyl group, or together with the nitrogen atom to which they are attached form a saturated 5 to 7 membered ring); and with the proviso that when Q represents a hydrogen atom R¹ represents -CO₂R⁸, -COR⁸, -CONR⁸R⁹ or -SO₂R⁸; and physiologically acceptable salts and solvates thereof. Suitable physiologically acceptable salts of the compounds of general formula (I) include acid addition salts formed with organic or inorganic acids for axample, hydrochlorides, hydrobromides, sulphates, alkyl- or arylsulphonates (e.g. methanesulphonates or p-toluenesulphonates), phosphates, acetates, citrates, succinates, tartrates, fumarates and maleates. The solvates may, for example, be hydrates. All optical isomers of compounds of general formula (I) and their mixtures including the racemic mixtures thereof, and all the geometric isomers of compounds of formula (I), are embraced by the invention. It will be appreciated that the invention extends to other physiologically acceptable equivalents of the compounds according to the invention, i.e. physiologically acceptable compounds which are converted in vivo into the parent compound of formula (I). Referring to the general formula (I), the alkyl groups represented by R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹ and Q may be straight chain or branched chain alkyl groups, for example, methyl, ethyl, propyl, prop-2-yl, butyl, but-2-yl or 2-methylprop-2-yl, and, in the case of R¹-R⁹ and Q, pentyl, pent-3-yl or hexyl. An alkenyl group may be, for example, a propenyl or butenyl group. An alkynyl group may be, for example, a prop-2-ynyl or oct-2-ynyl group. When R¹ represents a C 3-6 alkenyl group or a C 3-10 alkynyl group, or R¹⁰ or R¹¹ represents a C 3-4 alkenyl group, the double or triple bond may not be adjacent to the nitrogen atom. A phenylC 1-3 alkyl group (as such or as part of a phenylC 1-3 alkoxy group) may be, for example, a benzyl, phenethyl or 3-phenylpropyl group. A cycloalkyl group (as such or as part of a cycloalkylalkyl group) may be, for example, a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl group. When R¹ represents a C 3-7 cycloalkylC 1-4 alkyl group, the alkyl moiety may be, for example, a methyl, ethyl, propyl, prop-2-yl or butyl group. When Q represents a C 1-4 alkoxy group it may be, for example, a methoxy group. When Q represents a halogen atom it may be, for example a fluorine, chlorine bromine atom. The substituent Q may be at the 4, 5, 6 or 7 position of the indole moiety. A preferred class of compounds of formula (I) are those where R¹ represents a hydrogen atom or a C 1-3 alkyl, C 3-4 alkenyl, C 3-4 alkynyl, C 5-6 cycloalkyl, benzyl, N , N -diC 1-3 alkylcarboxamido or C 1-3 alkoxycarbonyl group. More preferably R¹ represents a C 1-3 alkyl (e.g. methyl), N , N -diC 1-3 alkylcarboxamido (e.g. N , N -dimethylcarboxamido) or C 1-3 alkoxycarbonyl (e.g. methoxycarbonyl group. Another preferred class of compounds of formula (I) are those wherein R² represents a hydrogen atom or a C 1-3 alkyl (e.g. methyl) group, more preferably a hydrogen atom. Another preferred class of compounds of formula (I) are those wherein R³ and R⁴ each independently represent a hydrogen atom or a C 1-3 alkyl (e.g. methyl) group. A particularly preferred class of compounds are those in which R³ and R⁴ both represent hydrogen atoms. A further preferred class of compounds of formula (I) are those wherein R⁵ represents a C 1-3 alkyl (e.g. methyl) group or, more preferably, a hydrogen atom. R⁶ preferably represents a C 1-3 alkyl (e.g. methyl) or, more preferably, a hydrogen atom. R⁷ preferably represents a hydrogen atom or a C 1-3 alkyl (e.g. methyl) group. When R⁵ and R⁶ represent hydrogen atoms, R⁷ is preferably a C 1-6 alkyl, C 3-7 cycloalkyl, C 3-6 alkenyl, or phenylC 1-3 alkyl group, more particularly C 1-3 alkyl (e.g. methyl). Another preferred class of compounds of formula (I) are those wherein Q represents a hydrogen atom, a halogen (e.g. fluorine) atom or a hydroxy, C 1-3 alkoxy (e.g. methoxy) or C 1-3 alkyl (e.g. methyl) group. More preferably Q represents a hydrogen or halogen (e.g. fluorine) atom or a C 1-3 alkyl (e.g. methyl) group. When Q is other than a hydrogen atom, it is preferably at the 5-, 6- or 7-position of the indole ring, more preferably the 5- or 7-position. A preferred group of compounds of formula (I) are those wherein R¹ represents a C 1-3 alkyl (e.g. methyl), N , N -diC 1-3 alkylcarboxamido (e.g. N , N -dimethylcarboxamido) or C 1-3 alkoxycarbonyl (e.g. methoxycarbonyl) group, more preferably a methyl group; R² represents a hydrogen atom; R³ and R⁴ both represent hydrogen atoms; R⁵ and R⁶ each represent a hydrogen atom; R⁷ represents a hydrogen atom or a C 1-3 alkyl group, more preferably a methyl group; and Q represents a hydrogen or halogen (e.g. fluorine) atom or a C 1-3 alkyl (e.g. methyl) group. A particularly preferred compound according to the invention is 3-(5-methyl-1 H -imidazol-4-yl)-1-(1,7-dimethyl-1 H -indol-3-yl)-propanone and its physiologically acceptable salts and solvates. Compounds of the invention are potent and selective antagonists or 5-HT-induced responses of the rat isolated vagus nerve preparation and thus act as potent and selective antagonists of the 'neuronal' 5-HT receptor type located on primary afferent nerves. Receptors of this type are now designated as 5-HT₃ receptors. Such receptors are also present in the central nervous system. 5-HT occurs widely in the neuronal pathways in the central nervous system and disturbance of these 5-HT containing pathways is known to alter behavioural syndromes such as mood, psychomotor activity, appetite and memory. Compounds of formula (I), which antagonise the effect of 5-HT at 5-HT₃ receptors, are useful in the treatment of conditions such as psychotic disorders (e.g. schizophrenia and mania); anxiety; and nausea and vomiting, particularly that associated with cancer chemotherapy and radiotherapy. Compounds of formula (I) are also useful in the treatment of gastric stasis; symptoms of gastrointestinal dysfunction such as occur with dyspepsia, peptic ulcer, reflux oesophagitis, flatulence and irritable bowel syndrome; migraine; and pain. Compounds of formula (I) may also be used in the treatment of dependency on drugs and substances of abuse, depression, and dementia and other cognitive disorders. Unlike existing drug treatments for certain of the above conditions, the compounds of the invention, because of their high selectivity for 5-HT₃ receptors, would not be expected to produce undesirable side effects. Thus, for example, neuroleptic drugs may cause extrapyramidal effects, such as tardive dyskinesia, and benzodiazepines may cause dependence. According to another aspect, the invention provides a method of treatment of a human or animal subject suffering from a psychotic disorder such as schizophrenia or mania; or from anxiety; nausea or vomiting, particularly that associated with cancer chemotherapy and radiotherapy; gastric stasis; symptoms of gastrointestinal dysfunction such as dyspepsia, reflux oesophagitis, peptic ulcer, flatulence oand irritable bowel syndrome; migraine; pain; dependency on drugs or substances of abuse; depression; or dementia and other cognitive disorders, which comprises administering an effective amount of a compound of formula (I) or a physiologically acceptable salt or solvate thereof. Accordingly, the invention also provides a pharmaceutical composition which comprises at least one compound selected from indole derivatives of the general formula (I), their physiologically acceptable salts and solvates (e.g. hydrates), for use in human or veterinary medicine, and formulated for administration by any convenient route. Such compositions may be formulated in conventional manner using one or more physiologically acceptable carriers and/or excipients. Thus the compounds according to the invention may be formulated for oral, buccal, parenteral, rectal or transdermal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or the nose). For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl- p -hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate. Preparations for oral administration may be suitably formulated to give controlled release of the active compound. For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner. The compounds of the invention may be formulated for parenteral administration by injection e.g. by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use. The compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides. In addition to the formulations described prviously, the compounds of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously, transcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. For administration by inhalation the compounds according to the invention are conveniently delivered in the form of an aerosol spray presentation from pressurised packs or a nebuliser, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurised aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch. For intranasal administration, the compounds according to the invention may be formulated as solutions for administration via a suitable metered or unit dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device. The compounds of formula (I) may also be administered in combination with other therapeutic agents. Thus, for example, in the treatment of gastric stasis, symptoms of gastrointestinal dysfunction and nausea and vomiting, the compounds of formula (I) may be administered in combination with antisecretory agents such as histamine H₂-receptor antagonists (e.g. ranitidine, sufotidine or loxtidine) or H⁺K⁺ATPase inhibitors (e.g. omeprazole). A proposed dose of the compounds of the invention for administration to man (of approximately 70kg body weight) is 0.001 to 100mg, preferably 0.01 to 50mg, most preferably 0.5 to 20mg of the active ingredient per unit dose (expressed as the weight of free base) which could be administered, for example, 1 to 4 times per day. The dose will depend on the route of administration and the condition being treated. It will be appreciated that it may be necessary to make routine variations to the dosage depending on the age and weight of the patient as well as the severity of the condition to be treated. According to another aspect of the invention, compounds of general formula (I), and physiologically acceptable salts or solvates thereof, may be prepared by the general methods outlined hereinafter. In the following description, the groups R¹ to R¹¹, Q and Im are as defined for compounds of general formula (I) unless otherwise stated. According to a first general process (A), a compound of general formula (I) may be prepared by reacting a compound of general formula (II): or a protected derivative thereof, with an acylating derivative of an acid of general formula (III) : or a salt or protected derivative thereof, followed where necessary by removal of any protecting groups. Suitable acylating derivatives of the acid (III) include acid halides (e.g. acid chlorides), anhydrides (e.g. symmetrical anhydrides or mixed anhydrides formed for example with pivaloyl chloride), amides, and nitriles. Thus for example indoles of formula (II) may be acylated according to the Vilsmeier-Haack reaction, using a tertiary amide derivative of an acid of formula (III), such as the corresponding N , N -dimethylpropanamide compound, or a salt thereof, in the presence of a phosphoryl halide such as phosphorous oxychloride. This reaction may be effected in the presence or absence of a solvent. Solvents which may conveniently be employed include halogenated hydrocarbons such as 1,2-dichloroethane. The reaction temperature may be in the range 20 to 100°C. According to another general process (B), a compound of general formula (I) wherein R¹ represents the group -CO₂R⁸,-COR⁸,-COR⁸R⁹ or -SO₂R⁸ may be prepared by acylating or sulphonylating as appropriate, a compound of formula (IV): or a protected derivative thereof, followed where necessary by removal of any protecting groups. The acylation/sulphonylation reaction may be effected using an appropriate acylating/sulphonylating agent according to conventional procedures. Suitable acylating agents include acyl halides (e.g. an acyl chloride, bromide or iodide), mixed and symmetrical anhydrides (e.g. a symmetrical anhydride of formula (R⁸CO)₂O), lower alkyl haloformates (e.g. lower alkyl chloroformates), carbamoyl halides (e.g. carbamoyl chlorides of formula R⁸R⁹NCOCl), carbonates and isocyanates (e.g. isocyanates of formula R⁸NCO). Suitable sulphonylating agents include sulphonyl halides (e.g. an alkylsulphonyl or arylsulphonyl chloride, bromide or iodide) and sulphonates (e.g. hydrocarbylsulphonates such as p -toluenesulphonate). The reaction may conveniently be effected in the presence of a base such as an alkali metal hydride (e.g. sodium or potassium hydride), an alkali metal carbonate (e.g. sodium or potassium carbonate), an alkali metal alkoxide (e.g. potassium t-butoxide), butyllithium, lithium diisopropylamide or an organic tertiary amine (e.g. triethylamine or pyridine). Suitable solvents which may be employed in the acylation/sulphonylation of general process (B) include substituted amides (e.g. dimethylformamide or dimethylacetamide), ethers (e.g. tetrahydrofuran or dioxan), halogenated hydrocarbons (e.g. methylene chloride), nitriles (e.g. acetonitrile) and esters (e.g. ethyl acetate). The reaction may conveniently be effected at a temperature of from -10 to +150°C. According to another general process (C), a compound of general formula (I) may be converted into another compound of formula (I) using conventional techniques. Such conventional techniques include hydrogenation, alkylation, acylation and acid-catalysed cleavage using protection and deprotection where necessary. Thus, according to one embodiment of the interconversion process (C), hydrogenation may be used to convert an alkenyl or an alkynyl substituent into an alkyl substituent or an alkynyl into an alkenyl substituent, or a benzyloxy substituent into a hydroxyl group. Hydrogenation according to general process (C) may be effected using conventional procedures, for example using hydrogen in the presence of a noble metal catalyst (e.g. palladium, Raney nickel, platinum or rhodium). The catalyst may be supported on, for example, charcoal, alumina or alternatively a homogeneous catalyst such as tris(triphenylphosphine)rhodium chloride may be used. The hydrogenation will generally be effected in a solvent such as an alcohol (e.g. methanol or ethanol), an ether (e.g. dioxan), a halogenated hydrocarbon (e.g. dichloromethane) or an ester (e.g. ethyl acetate) or mixtures thereof, and at a temperature in the range -20 to +100°C, preferably 0 to 50°C. According to another embodiment of the interconversion process (C), a compound of formula (I) in which R¹ represents a C 1-6 alkyl, C 3-7 cycloalkyl, C 3-6 alkenyl, C 3-10 alkynyl, C 3-7 cycloalkylC 1-4 -alkyl or phenylC 1-3 alkyl group, or a compound in which at least one of R³ and R⁴ represents a C 1-6 alkyl group, or a compound in which at least one of R⁵ and R⁶ represents a C 1-6 alkyl, C 3-7 cycloalkyl, C 3-6 alkenyl or phenyl C 1-3 alkyl group, or a compound in which Q represents a C 1-4 alkoxy or a phenylC 1-3 alkoxy group, or a compound in which R¹⁰ and/or R¹¹ represents a C 1-4 alkyl or C 3-4 alkenyl group may be prepared by alkylating a compound of formula (I) where one or more of R¹, R³, R⁴, R⁵, R⁶, R¹⁰ and R¹¹ represent a hydrogen atom, or Q represents a hydroxyl group. The term 'alkylation' according to general process (C) thus also includes the introduction of other groups such as cycloalkyl, alkenyl or phenalkyl groups. The above alkylation reactions may be effected using the appropriate alkylating agent selected from compounds of formula R¹²Z where R¹² represents a C 1-6 alkyl, C 3-7 cycloalkyl, C 3-6 alkenyl, C 3-10 alkynyl, C 3-7 cycloalkylC 1-4 alkyl, or phenylC 1-3 alkyl group, and Z represents a leaving atom or group such as a halogen atom (e.g. chlorine, bromine or iodine), an acyloxy group (e.g. trifluoroacetyloxy or acetoxy), or a sulphonyloxy group (e.g. trifluoromethanesulphonyloxy, p -toluenesulphonyloxy or methanesulphonyloxy); or a sulphate of formula (R¹²)₂SO₄. The alkylation reaction is conveniently carried out in an inert organic solvent such as a substituted amide (e.g. dimethylformamide), an ether (e.g. tetrahydrofuran) or an aromatic hydrocarbon (e.g. toluene), preferably in the presence of a base. Suitable bases included, for example, alkali metal hydrides (e.g. sodium hydride), alkali metal amides (e.g. sodium amide or lithium diisopropylamide), alkali metal carbonates (e.g. sodium carbonate) or an alkali metal alkoxide (e.g. sodium or potassium methoxide, ethoxide or t-butoxide). The reaction may conveniently be effected at a temperature in the range -80 to +100°C, preferably -80 to +50°C. According to another embodiment of general process (C), a compound of formula (I) wherein R¹ represents -CO₂R⁸, -COR⁸, -CONR⁸R⁹ or -SO₂R⁸ and Q is other than a hydrogen atom, may be prepared by acylating or sulphonylating a compound of formula (I) wherein R¹ represents a hydrogen atom. The acylation reactions may be effected using an appropriate acylating or sulphonylating agent according to conventional procedures as described, for example, in general process (B). According to a yet further embodiment of general process (C), a compound of formula (I) in which Q represents a hydroxyl group may be prepared from the corresponding compound in which Q represents an alkoxy or benzyloxy group by acid-catalysed cleavage. The reaction may be effected using a Lewis acid such as boron tribromide or aluminium trichloride, in a solvent such as a halogenated hydrocarbon (e.g. dichloromethane). The reaction temperature may conveniently be in the range -80 to +100°C. It should be appreciated that in the above transformations it may be necessary or desirable to protect any sensitive groups in the molecule of the compound in question to avoid undesirable side reactions. For example, it may be necessary to protect the keto group, for example, as a ketal or a thioketal. It may also be necessary to protect the indole and/or imidazole nitrogen atoms, for example with an arylmethyl (e.g. benzyl or trityl), alkyl (e.g. t-butyl), alkoxymethyl (e.g. methoxymethyl), acyl (e.g. benzyloxycarbonyl) or a sulphonyl (e.g. N , N -dimethylaminosulphonyl or p -toluenesulphonyl) group. When Q represents a hydroxyl group it may be necessary to protect the hydroxyl group, for example with an arylmethyl (e.g. benzyl or trityl) group. Thus according to another general process (D), a compound of general formula (I) may be prepared by the removal of any protecting groups from a protected form of a compound of formula (I). Deprotection may be effected using conventional techniques such as those described in 'Protective Groups in Organic Synthesis' by Theodora W. Greene (John Wiley and Sons, 1981). For example a ketal such as an alkyleneketal group may be removed by treatment with a mineral acid such as hydrochloric acid. A thioketal group may be cleaved by treatment with a mercuric salt, (e.g. mercuric chloride), in a suitable solvent, such as ethanol. An arylmethyl N -protecting group may be cleaved by hydrogenolysis in the presence of a catalyst (e.g. palladium on charcoal) and a trityl group may also be cleaved by acid hydrolysis (e.g. using dilute hydrochloric or acetic acid). An alkoxyalkyl group may be removed using a Lewis acid such as boron tribromide. An acyl group may be removed by hydrolysis under acidic or basic conditions (e.g. using hydrogen bromide or sodium hydroxide). A sulphonyl group may be removed by alkaline hydrolysis. An arylmethyl OH-protecting group may be cleaved under acidic conditions (e.g. with dilute acetic acid, hydrobromic acid or boron tribromide) or by hydrogenolysis in the presence of a catalyst (e.g. palladium on charcoal). Compounds of general formula (II) are either known or may be prepared from known compounds by conventional procedures. Acylating derivatives of the acids of formula (III), as well as the acids (III), and compounds of general formula (IV) in which Q represents a hydrogen atom may be prepared, for example, by the methods described in published European Patent Specification No. 242973. Where it is desired to isolate a compound of the invention as a salt, for example a physiologically acceptable salt, this may be achieved by reacting the compound of formula (I) in the form of the free base with an appropriate acid, preferably with an equivalent amount, in a suitable solvent such as an alcohol (e.g. ethanol or methanol), an aqueous alcohol (e.g. aqeous ethanol), an ester (e.g. ethyl acetate) or an ether (e.g. tetrahydrofuran). Physiologically acceptable salts may also be prepared from other salts, including other physiologically acceptable salts, of the compound of formula (I) using conventional methods. Individual enantiomers of the compounds of the invention may be obtained by resolution of a mixture of enantiomers (e.g. a racemic mixture) using conventional means, such as an optically active resolving acid; see for example 'Stereochemistry of Carbon Compounds' by E.L.Eliel (McGraw Hill 1962) and 'Tables of Resolving Agents' by S. H. Wilen. The methods indicated above for preparing the compounds of the invention can be used as the last main step in the preparative sequence. The same general methods can be used for the introduction of the desired groups at an intermediate stage in the stepwise formation of the required compound, and it will be appreciated that these general methods can be combined in different ways in such multi-stage processes. The sequence of the reactions in multi-stage processes should of course be chosen so that the reaction conditions used do not affect groups in the molecule which are desired in the final product. The invention is further illustrated by the following Examples. All temperatures are in °C. Thin layer chromatography (t.l.c.) was carried out over silica, and flash column chromatography (FCC) on silica (Merck 9385). Solvent System A as used for chromatography denotes dichloromethane:ethanol:0.88 ammonia solution. Organic extracts were dried over sodium sulphtae or magnesium sulphate. The following abbreviations are used: DMF-dimethylformamide, THF-tetrahydrofuran. Example 1 3-(5-Methyl-1 H -imidazol-4-yl)-1-(1,7-dimethyl-1 H -indol-3-yl)propanone maleate A solution of N , N -dimethyl-3-(5-methyl-1 H -imidazol-4-yl)-1-propanamide (300mg) in ethanol (15mℓ) was acidified (to pH 1) by the addition of ethanolic hydrogen chloride, and evaporated to yield an oil which was triturated with ether to give N , N - dimethyl-3-(5-methyl-1 H -imidazol-4-yl)-1-propanamide dihydrochloride (270mg) as a powder. This was added to a mixture of 1,7-dimethylindole (195mg) and phosphorus oxychloride (0.15mℓ) and the mixture was heated at 85° in a closed vessel for 1.5h. The mixture was cooled, cold water (50mℓ) was added and the suspension was stirred for 0.5h. It was then washed with ethyl acetate (2x40mℓ; discarded), basified with 2N sodium carbonate and extracted with ethyl acetate (4x80mℓ). The combined, dried organic extracts were evaporated to give the free base of the title compound (232mg) as a solid which was dissolved in hot ethanol (15mℓ), and maleic acid (105mg) in warm ethanol (5mℓ) was added. The solution was evaporated and the residual solid was crystallised from ethanol (15mℓ) to give the title compound (235mg), m.p. 164-165°. Analysis Found: C,63.4; H,5.9; N,10.5. C₁₇H₁₉N₃O.C₄H₄O₄ requires C,63.5; H,5.8; N,10.6%. Examples 2,3,4 and 5 were prepared in a similar manner to Example 1. Example 2 3-(5-Methyl-1 H -imidazol-4-yl)-1-(1,6-dimethyl-1 H -indol-3-yl)propanone maleate N , N -Dimethyl-3-(5-methyl-1 H -imidazol-4-yl)-1- propanamide (255mg) was converted to its dihydrochloride and reacted with 1,6-dimethyl-1 H -indole (250mg) and phosphorus oxychloride (0.19mℓ) at 85° for 2.5h. Work-up and salt formation gave the title compound (247mg), m.p. 167-168°. Analysis Found: C,63.3; H,5.9; N,10.4. C₁₇H₁₉N₃O.C₄H₄O₄ requires C,63.5; H,5.8; N,10.6%. Example 3 3-(5-Methyl-1 H -imidazol-4-yl)-1-(5-fluoro-1-methyl-1 H -indol-3-yl)propanone maleate The reaction of N , N -dimethyl-3-(5-methyl-1 H -imidazol-4-yl)-1-propanamide dihydrochloride (505mg), 5-fluoro-1-methyl-1 H -indole (350mg) and phosphorus oxychloride (0.23mℓ) followed by work-up and salt formation gave the title compound (483mg), m.p. 172-173°. Analysis Found: C,59.9; H,5.1; N,10.3. C₁₆H₁₆FN₃O.C₄H₄O₄ requires C,59.9; H,5.0; N,10.5%. Example 4 3-(5-Methyl-1 H -imidazol-4-yl)-1-(1,5-dimethyl-1 H -indol-3-yl)propanone maleate The reaction of N , N -dimethyl-3-(5-methyl-1 H -imidazol-4-yl)-1-propanamide dihydrochloride (317mg), 1,5-dimethyl-1 H -indole (220mg) and phosphorus oxychloride (0.17mℓ) followed by work-up and salt formation gave the title compound (327mg), m.p. 168-169°. Analysis Found: C,63.2; H,5.8; N,10.7. C₁₇H₁₉N₃O.C₄H₄O₄ requires C,63.5; H,5.8; N,10.6%. Example 5 3-(1 H -Imidazol-4-yl)-1-(5-fluoro-1-methyl-1 H -indol-3-yl)propanone maleate The reaction of N , N -dimethyl-3-(1 H -imidazol-4-yl)-1-propanamide hydrochloride (220mg), and 5-fluoro-1-methyl-1 H -indole (146mg) and phosphorus oxychloride (0.10mℓ) followed by work-up and salt formation gave the title compound (200mg). Further recrystallisation from ethanol (8ml) gave the title compound (120mg), m.p. 153-154°. Analysis Found : C,58.7; H,4.7; N,10.6. C₁₅H₁₄FN₃O.C₄H₄O₄ requires C,58.9; H,4.7; N,10.4%. Example 6 1-(1-Methoxycarbonyl-1 H -indol-3-yl)-3-(5-methyl-1 H -imidazol-4-yl)-1-propanone maleate A suspension of 3-[5-methyl-1-(triphenylmethyl)-1 H -imidazol-4-yl]-1-(1 H -indol-3-yl)-1-propanone (500mg) in dry DMF (3mℓ) was added dropwise to a stirred suspension of sodium hydride (73% dispersion in oil; 40mg) in dry DMF (1mℓ) under nitrogen. After 15 min. methyl chloroformate (0.093mℓ) was added and the mixture was stirred for 4.5h. Water (50mℓ) was added and the suspension was extracted with dichloromethane (3x25mℓ). The combined, dried organic extracts were evaporated to give an oil ( ca . 710mg) which was purified by FCC (column made up in ethyl acetate:hexane:triethylamine 80:19:1) eluting with ethyl acetate:hexane (4:1) to give a foam (320mg). This was dissolved in a mixture of dry THF (9mℓ), acetic acid (9mℓ) and water (9mℓ) and heated at reflux for 1h. The mixture was poured into saturated potassium carbonate solution (60mℓ) and extracted with dichloromethane (3x30mℓ). The combined, dried organic extracts were dried to give a solid (288mg) which was purified by FCC eluting with System A (200:10:1) to give a solid (174mg). This was dissolved in ethanol (2mℓ) and treated with a solution of maleic acid (68mg) in ethanol (0.5mℓ). The solvent was removed in vacuo and the residue was triturated with dry ether (3x5mℓ) to give the title compound (180mg), m.p. 167-169°. Water Assay Found 1.38% w/w ≡ 0.33mol H₂O. Analysis Found C,58.0; H,4.9; N,9.5. C₁₇H₁₇N₃O₃.C₄H₄O₄.O.33H₂O requires C,58.2; H,5.0; N,9.7%. Example 7 N , N -Dimethyl-3-[3-(5-methyl-1 H -imidazol-4-yl]-1-oxopropyl]-1 H -indole-1-carboxamide maleate (i) N , N -Dimethyl-3-[3-[5-methyl-1-(triphenylmethyl)-1 H -imidazol-4-yl]-1-oxopropyl]-1 H -indole-1-carboxamide A solution of 3-[5-methyl-1-(triphenylmethyl)-1 H -imidazol-4-yl]-1-(1 H -indol-3-yl)-1-propanone (500mg) in dry DMF (3mℓ) was added dropwise to a stirred suspension of sodium hydride (73% dispersion in oil; 40mg) in dry DMF (1mℓ) under nitrogen. After 15 min. dimethylcarbamyl chloride (0.11mℓ) was added and the mixture was stirred for 20h. Water (50mℓ) was added and the suspension was extracted with dichloromethane (3 x 25mℓ). The combined, dried organic extracts were evaporated to give an oil (815mg) which was purified by FCC (column made up in ethyl acetate:triethylamine 99:1) eluting with ethyl acetate to give the title compound (445mg) as a foam, t.l.c. on triethylamine impregnated silica (ethyl acetate) Rf 0.20. (ii) N , N -Dimethyl-3-[3-(5-methyl-1 H -imidazol-4-yl]-1-oxopropyl]-1 H -indole-1-carboxamide maleate A solution of N , N -dimethyl-3-[3-[5-methyl-1-(triphenylmethyl)-1 H -imidazol-4-yl]-1-oxopropyl]-1 H -indole-1-carboxamide (400mg) in a mixture of acetic acid (12mℓ), water (12mℓ) and THF (12mℓ) was heated at reflux for 3h. The mixture was poured into saturated potassium carbonate solution (80mℓ) and extracted with dichloromethane (3 x 40mℓ). The combined, dried organic extracts were evaporated to give a gum (420mg) which was purified by FCC eluting with System A (200:10:1) to give an oil (200mg). This was dissolved in ethanol ( ca . 3mℓ) and treated with a solution of maleic acid (75mg) in ethanol ( ca . 1mℓ). The solvent was removed in vacuo and the residue was triturated with dry ether (5 x 5mℓ) to give the title compound (218mg), m.p. 129-130°. Analysis Found: C,59.9; H,5.7; N,12.4. C₁₈H₂₀N₄O₂.C₄H₄O₄ requires C,60.0; H,5.5; N,12.7%. The following examples illustrate pharmaceutical formulations according to the invention. The term "active ingredient" is used herein to represent a compound of formula (I). TABLETS FOR ORAL ADMINISTRATION Tablets may be prepared by the normal methods such as direct compression or wet granulation. The tablets may be film coated with suitable film forming materials, such as hydroxypropyl methylcellulose, using standard techniques. Alternatively the tablets may be sugar coated. The active ingredient is passed through a 60 mesh sieve, blended with the calcium hydrogen phosphate, croscarmellose sodium and magnesium stearate. The resultant mix is compressed into tablets using a Manesty F3 tablet machine fitted with 5.5mm, flat bevelled edge punches. Tablets of other strengths may be prepared by altering the ratio of active ingredient to excipients or the compression weight and using punches to suit. CAPSULES The active ingredient is sieved and blended with the excipients. The mix is filled into size No. 2 hard gelatin capsules using suitable machinery. Other doses may be prepared by altering the fill weight and if necessary changing the capsule size to suit. SYRUP This may be either a sucrose or sucrose free presentation. The hydroxypropylmethylcellulose is dispersed in hot water, cooled and then mixed with an aqueous solution containing the active ingredient and the other components of the formulation. The resultant solution is adjusted to volume and mixed. The syrup is clarified by filtration. INJECTION FOR INTRAVENOUS ADMINISTRATION Sodium chloride may be added to adjust the tonicity of the solution and the pH may be adjusted, using acid or alkali, to that of optimum stability and/or facilitate solution of the active ingredient. Alternatively, suitable buffer salts may be used. The solution is prepared, clarified and filled into appropriate size ampoules sealed by fusion of the glass. The injection is sterilised by heating in an autoclave using one of the acceptable cycles. Alternatively, the solution may be sterilised by filtration and filled into sterile ampoules under aseptic conditions. The solution may be packed under an inert atmosphere of nitrogen or other suitable gas.

Claims: Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE Compounds of the general formula (I): wherein Im represents an imidazolyl group of formula : R¹ represents a hydrogen atom or a group selected from C 1-6 alkyl, C 3-6 alkenyl, C 3-10 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-4 alkyl, phenyl, phenylC 1-3 alkyl, -CO₂R⁸, -COR⁸, -CONR⁸R⁹ or -SO₂R⁸ (wherein R⁸ and R⁹, which may be the same or different, each represents a hydrogen atom, a C 1-6 alkyl or C 3-7 cycloalkyl group, or a phenyl or phenylC 1-4 alkyl group, in which the phenyl group is optionally substituted by one or more C 1-4 alkyl, C 1-4 alkoxy or hydroxy groups or halogen atoms, with the proviso that R⁸ does not represent a hydrogen atom when R¹ represents a group -CO₂R⁸ or -SO₂R⁸); R₂ represents a hydrogen atom or a C 1-6 alkyl, C 3-6 alkenyl, C 3-7 cycloalkyl, phenyl or phenylC 1-3 alkyl group; R³ and R⁴, which may be the same or different, each represents a hydrogen atom or a C 1-6 alkyl group; one of the gruops represented by R⁵, R⁶ and R⁷ is a hydrogen atom or a C 1-6 alkyl, C 3-7 cycloalkyl, C 3-6 alkenyl, phenyl or phenylC 1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C 1-6 alkyl group; Q represents a hydrogen atom or a halogen atom or a hydroxy, C 1-4 alkoxy, phenylC 1-3 alkoxy or C 1-6 alkyl group or a group -NR¹⁰R¹¹ or -CONR¹⁰R¹¹ (wherein R¹⁰ and R¹¹, which may be the same or different, each represents a hydrogen atom or a C 1-4 alkyl or C 3-4 alkenyl group, or together with the nitrogen atom to which they are attached form a saturated 5 to 7 membered ring); and with the proviso that when Q represents a hydrogen atom R¹ represents -CO₂R⁸, -COR⁸, -CONR⁸R⁹ or -SO₂R⁸; and physiologically acceptable salts and solvates thereof. Compounds as claimed in claim 1 in which R¹ represents a hydrogen atom or a C 1-3 alkyl, C 3-4 alkenyl, C 3-4 alkynyl, C 5-6 cycloalkyl, benzyl, N , N -diC 1-3 alkylcarboxamido or C 1-3 alkoxycarbonyl group. Compounds as claimed in claim 1 or 2 in which R² represents a hydrogen atom or a C 1-3 alkyl group. Compounds as claimed in any of claims 1 to 3 in which R³ and R⁴ each independently represent a hydrogen atom or a C 1-3 alkyl group. Compounds as claimed in any of claims 1 to 4 in which R⁵, R⁶ and R⁷ each represent a hydrogen atom or a C 1-3 alkyl group. Compounds as claimed in any of claims 1 to 4 in which R⁵ and R⁶ both represent hydrogen atoms and R⁷ represents a C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₆alkenyl, or phenylC₁₋₃alkyl group. Compounds as claimed in any of claims 1 to 6 in which Q represents a hydrogen atom, a halogen atom or a hydroxy, C₁₋₃alkoxy or C₁₋₃alkyl group. Compounds as claimed in claim 1 in which R¹ represents a C₁₋₃alkyl, N , N -diC₁₋₃alkylcarboxamido or C₁₋₃alkoxycarbonyl group; R² represents a hydrogen atom; R³ and R⁴ both represent hydrogen atoms; R⁵ and R⁶ each represent a hydrogen atom; R⁷ represents a hydrogen atom or a C₁₋₃alkyl group; and Q represents a hydrogen or a halogen atom or a C₁₋₃alkyl group. A compound as claimed in claim 1 which is 3-(5-methyl-1 H -imidazol-4-yl)-1-(1,7-dimethyl-1 H -indol-3-yl)propanone or a physiologically acceptable salt or solvate thereof. A process for the preparation of a compound of general formula (I) as defined in any of claims 1 to 9 or a physiologically acceptable salt or solvate thereof, which comprises: (A) reacting a compound of general formula (II) or a protected derivative thereof with an acylating derivative of an acid of general formula (III) or a salt or protected derivative thereof, followed if necessary by removal of any protecting groups present; or (B) for the preparation of a compound of formula (I) in which R¹ represents the group -CO₂R⁸, -COR⁸, -COR⁸R⁹ or -SO₂R⁸, acylating or sulphonylating as appropriate a compound of formula (IV) or a protected derivative thereof, followed if necessary by removal or any protecting groups present; or (C) converting a compound of formula (I) or a salt or protected derivative thereof into another compound of formula (I) using conventional techniques; or (D) removing protecting group(s) from a protected form of a compound of formula (I); and, when the compound of formula (I) is obtained as a mixture of enantiomers, optionally resolving the mixture to obtain the desired enantiomer; and/or where the compound of formula (I) is in the form of a free base, optionally converting the free base into a salt. A pharmaceutical composition comprising at least one compound of general formula (I) as defined in any of claims 1 to 9 or a physiologically acceptable salt or solvate thereof together with at least one physiologically acceptable carrier or excipient. A compound of general formula (I) as defined in claim 1 for use as an active therapeutic agent. Claims for the following Contracting States : ES, GR A process for the preparation of compounds of the general formula (I): wherein Im represents an imidazolyl group of formula : R¹ represents a hydrogen atom or a group selected from C 1-6 alkyl, C 3-6 alkenyl, C 3-10 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-4 alkyl, phenyl, phenylC 1-3 alkyl, -CO₂R⁸, -COR⁸, -CONR⁸R⁹ or -SO₂R⁸ (wherein R⁸ and R⁹, which may be the same or different, each represents a hydrogen atom, a C 1-6 alkyl or C 3-7 cycloalkyl group, or a phenyl or phenylC 1-4 alkyl group, in which the phenyl group is optionally substituted by one or more C 1-4 alkyl, C 1-4 alkoxy or hydroxy groups or halogen atoms, with the proviso that R⁸ does not represent a hydrogen atom when R¹ represents a group -CO₂R⁸ or -SO₂R⁸); R₂ represents a hydrogen atom or a C 1-6 alkyl, C 3-6 alkenyl, C 3-7 cycloalkyl, phenyl or phenylC 1-3 alkyl group; R³ and R⁴, which may be the same or different, each represents a hydrogen atom or a C 1-6 alkyl group; one of the groups respresented by R⁵, R⁶ and R⁷ is a hydrogen atom or a C 1-6 alkyl, C 3-7 cycloalkyl, C 3-6 alkenyl, phenyl or phenylC 1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C 1-6 alkyl group; Q represents a hydrogen atom or a halogen atom or a hydroxy, C 1-4 alkoxy, phenylC 1-3 alkoxy or C 1-6 alkyl group or a group -NR¹⁰R¹¹ or -CONR¹⁰R¹¹ (wherein R¹⁰ and R¹¹, which may be the same or different, each represents a hydrogen atom or a C 1-4 alkyl or C 3-4 alkenyl group, or together with the nitrogen atom to which they are attached form a saturated 5 to 7 membered ring); and with the proviso that when Q represents a hydrogen atom R¹ represents -CO₂R⁸, -COR⁸, -CONR⁸R⁹ or -SO₂R⁸; and physiologically acceptable salts and solvates thereof, which comprises: (A) reacting a compound of general formula (II) or a protected derivative thereof with an acylating derivative of an acid of general formula (III) or a salt or protected derivative thereof, followed if necessary by removal of any protecting groups present; or (B) for the preparation of a compound of formula (I) in which R¹ represents the group -CO₂R⁸, -COR⁸, -COR⁸R⁹ or -SO₂R⁸, acylating or sulphonylating as appropriate a compound of formula (IV) or a protected derivative thereof, followed if necessary by removal or any protecting groups present; or (C) converting a compound of formula (I) or a salt or protected derivative thereof into another compound of formula (I) using conventional techniques; or (D) removing protecting group(s) from a protected form of a compound of formula (I); and, when the compound of formula (I) is obtained as a mixture of enantiomers, optionally resolving the mixture to obtain the desired enantiomer; and/or where the compound of formula (I) is in the form of a free base, optionally converting the free base into a salt. A process as claimed in claim 1 for the production of compounds in which R¹ represents a hydrogen atom or a C 1-3 alkyl, C 3-4 alkenyl, C 3-4 alkynyl, C 5-6 cycloalkyl, benzyl, N , N -diC 1-3 alkylcarboxamido or C 1-3 alkoxycarbonyl group. A process as claimed in claim 1 or 2 for the production of compounds in which R² represents a hydrogen atom or a C 1-3 alkyl group. A process as claimed in any of claims 1 to 3 for the production of compounds in which R³ and R⁴ each independently represent a hydrogen atom or a C 1-3 alkyl group. A process as claimed in any of claims 1 to 4 for the production of compounds in which R⁵, R⁶ and R⁷ each represent a hydrogen atom or a C 1-3 alkyl group. A process as claimed in any of claims 1 to 4 for the production of compounds in which R⁵ and R⁶ both represent hydrogen atoms and R⁷ represents a C 1-6 alkyl, C 3-7 cycloalkyl, C 3-6 alkenyl, or phenylC 1-3 alkyl group. A process as claimed in any of claims 1 to 6 for the production of compounds in which Q represents a hydrogen atom, a halogen atom or a hydroxy, C 1-3 alkoxy or C 1-3 alkyl group. A process as claimed in claim 1 for the production of compounds in which R¹ represents a C 1-3 alkyl, N , N -diC 1-3 alkylcarboxamido or C 1-3 alkoxycarbonyl group; R² represents a hydrogen atom; R³ and R⁴ both represent hydrogen atoms; R⁵ and R⁶ each represent a hydrogen atom; R⁷ represents a hydrogen atom or a C 1-3 alkyl group; and Q represents a hydrogen or a halogen atom or a C 1-3 alkyl group. A process as claimed in claim 1 for the production of 3-(5-methyl-1 H -imidazol-4-yl)-1-(1,7-dimethyl-1 H -indol-3-yl)propanone and physiologically acceptable salts and solvates thereof.

Inventors: CAVALLA, DAVID JOHN, OXFORD, ALEXANDER WILLIAM
Applicants: GLAXO GROUP LIMITED
Application year: 1988
Main classification: C07D403
IPC codes: A61P25, A61P1, A61K31, C07D403